# Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection

> **NCT04456413** · PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 21 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Convalescent Plasma
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT04456413
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-06
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-05-04
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456413, "Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04456413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*